Drug Discovery
ByCan Novartis AG’s $3 Billion AI-Driven Oncology Bet Redefine Precision Breast Cancer Treatment and Accelerate Next-Gen Drug Discovery?
Key Highlights: AI-Led Drug Discovery Accelerates Target Identification and ValidationNovartis AG’s acquisition of SNV4818 from Synnovation Therapeutics, Inc.…
How Will Emerging Drug Pricing Policies Reshape the Global Biopharma Industry in the Near and Long Term?
The global biopharmaceutical industry is entering a new policy-driven era as governments intensify efforts to control drug costs,…
Indian Biopharma Faces Freight Surge Amid US-Iran Escalation
India’s biopharma sector confronts $300-500M export losses as US-Iran war disrupts Gulf shipping, spiking container surcharges to $3,500–$5,000…
What broader implications does Zealand Pharma’s petrelintide trial setback raise for the GLP-1 obesity market?
Trial Context Recap ZUPREME-1 delivered 10.7% peak weight loss over 42 weeks across 493 patients, surpassing placebo but…
Can Sanofi SA’s $1.2 Billion AI-Driven Autoimmune Alliance with Kali Therapeutics Inc Unlock Next-Gen Tri-Specific Antibody Therapies and Disrupt Immunology Markets?
Key Highlights: AI-Powered Biologics Platforms Accelerate Next-Gen Antibody DiscoverySanofi SA’s licensing agreement with Kali Therapeutics Inc highlights the…
Can Eli Lilly and Company’s “Triple-G” AI-Enabled Next-Gen Drug Deliver 15%+ Weight Loss and Redefine the $100B Obesity-Diabetes Market Dominated by Novo Nordisk A/S?
Key Highlights: AI-Driven Clinical Design Unlocks Superior Metabolic OutcomesEli Lilly and Company’s late-stage trial results for retatrutide highlight…
